UNLEASHING THE FULL POTENTIAL
OF PSYCHEDELIC MUSHROOMS

WE ARE PSYGA BIO

PsygaBio is a drug discovery company focused on developing groundbreaking therapeutics derived from natural compounds. Founded by world-renowned cannabis and mushrooms researcher and pioneer Prof. Dedi Meiri from the Technion – Israel Institute of Technology and backed by robust scientific capabilities.

PsygaBio using Cannasoul’s proprietary analytical platform, data-driven approach, unique knowhow and clinical trial framework supports active compound identification and development, from mushrooms cultivation and extraction for clinical approved formulations.

Play Video

OUR MISSION

DISCOVERING EFFECTIVE AND INNOVATIVE THERAPIES
FROM PSYCHEDELIC MUSHROOMS

OUR DEVELOPMENT METHODOLOGY

GENETIC
DIVERSITY

CHEMICAL
ANALYTICS

ISOLATIONS
AND SYNTHESIS

FUNCTIONAL
BIOLOGICAL SCREENING

CLINICAL
TRIALS

Psilocybin and psilocin, major active metabolites in psychedelic mushrooms are gaining attention as potential therapy for many psychiatric conditions. These molecules are a part of a variety of tryptamine alkaloids, found in mushrooms, analogs to the naturally occurring neurotransmitter molecule Serotonin. Serotonin and serotonin receptors are important in the regulation of virtually all brain functions and many more of the body’s organs and systems such as immune responses, heart, kidneys and the digestive system.

PsygaBio in partnership with Cannasoul analytics aims to exploits the diversity found in the psychedelic mushroom realm to identify active compounds and formulations for therapeutic benefits.

Revolutionizing Mental Health with Botanical Solutions

PsygaBio is on a mission to replace outdated SSRIs with our proprietary, botanical-derived molecules. Harnessing the therapeutic power of psilocybin mushrooms, our solutions offer unparalleled benefits.

PSYGABIO SCIENTIFIC CAPABILITIES

GENETIC DIVESITY

State of the art growing and research facilities, creating and stabilizing new mushroom strains to create a Robust Bio Bank, following GAP and GMP guidelines.

EXTRACTION, ISOLATION
SYNTHESIS OF SMALL MOLECULES

Proprietary knowledge of extraction, separation, isolation and synthesis technologies that allow isolation of specific compounds from the psychedelic mushrooms.

CHEMOANALYTICS

Developing analytical methods for psilocybin mushrooms. Analytical expertise is essential for developing mushrooms derived pharmaceutical products. PsygaBio has developed validated analytical methods for the identification and quantification of the major mushroom derived tryptamines and is researching dozens more unknown active metabolites.

BIOLOGICAL SCREENING

Pre-clinical screening of psilocybin extracts, isolated novel molecules on various cell line models in collaboration with Cannasoul and Prof. Meiri’s lab in the Technion – Israel Institute of Technology.

HIGHLY EXPERIENCED MANAGEMENT
AND R&D TEAM

Dr. Shmuel Mandel

Founder

15 years of experience leading medical companies, Former VP Marketing & BD at DNR Bio Imagine, CEO & VP Marketing at AptaTeck Bio, VP of M&S at Rhenium, PhD in biochemistry and neuroscience

Prof. Dedi Meiri

CSO & Founder

Leading KOL in cannabis research, Head of the Cancer Biology and Cannabinoid Research Lab, Technion, Heads up Cannabis DB project, MSc in biochemistry, PhD in plant biology, Post doc at Ontario Cancer Institute

Dr. Isaac (Tzachy) Tal

CEO

Dr. Tal brings diverse entrepreneurial and scientific experience in biochemistry and molecular biology to the Psyga leadership team. Prior to Psyga, Dr. Tal was co-founder and CEO of Tamarix Pharma ltd developing novel technologies that restore physiological balance in apoptosis-related diseases, and co-founder and CEO of TPCera Ltd., which focused on developing novel immunomodulatory compounds to treat autoimmune diseases. During his tenure, Dr. Tal raised seed and round A funding to support the company’s technological, regulatory, clinical, financial, production, marketing, and business development activities. Dr. Tal was also the CEO of Gynamics, where he led all strategic and financial initiatives to advance the company’s medical device toward CE and FDA approval. Prior to his roles in the biotechnology industry, Dr. Tal served as Director of Business Development for the Technion – Israel Institute of Technology and for the Alfred Mann Institute for Biomedical Innovation.

Dr. Tal holds a PhD in Biochemistry and an MBA with specialization in Entrepreneurship and Finance from the Hebrew University of Jerusalem.

Dr. Rotem Perry Feigenbaum

VP Analytics & Development

Extensive experience in analytical research, Over 10 years of R&D expertise, Former head of analytical    dpt. at Virdia, PhD in organic chemistry

Dr. Yaniv Lerenthal

VP R&D

Extensive experience in plant and human genomics and cancer research. Former R&D lead  at bioinformatics lab at Kaiima bio agritech. Experienced in bioinformatics and data science. PhD in human genetics and cellular biology. Post doc at the cancer research center, Sheba medical center

Ido Taran

Researcher

Experience in fungal physiology and molecular biology. Specializes in mushrooms cultivation. MSc in microbiology and fungal physiology

Looz Milay

Project Manager

Project manager in the Cannabis and psychedelic mushrooms R&D field with extensive experience in development of extraction technologies and chemical analytics. MSc from the Technion in Prof. David (Dedi) Meiri’s lab

Liron Sulimani

Head of Bioanalytics and Development

Extensive background in various techniques in the analytical chemistry, Bioanalytical testing and identification of unknown compounds using high-end technology, especially Mass-Spectrometry. PhD candidate in the faculty of Biology, Technion, Israel.

Shira Yarimi

Research Assistance

NEWSROOM